Drug intelligence / Profile preview

COVID-19 vaccine (Vero cell), inactivated

Development stage
Phase 4
Lead developer
Sinopharm
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

COVID-19 vaccine (Vero cell), inactivated refers to a class of whole-virion inactivated vaccines developed to prevent COVID-19. These vaccines are produced by growing SARS-CoV-2 in Vero cell cultures, followed by chemical inactivation (typically with beta-propiolactone) to render the virus non-infectious while preserving its antigenic structure. The resulting inactivated virus is purified and usually formulated with an aluminum hydroxide adjuvant. Prominent examples include Sinovac's CoronaVac and Sinopharm's BBIBP-CorV (COVILO). By presenting the entire inactivated virus to the immune system, these vaccines elicit a broad immune response against multiple viral proteins, including the spike (S), nucleocapsid (N), envelope (E), and membrane (M) proteins, leading to the production of neutralizing antibodies and activation of T-cell mediated immunity.

Brand names
CoronaVacCOVILOHayat-VaxKCONVAC
Other names
Inactivated SARS-CoV-2 vaccine (Vero cell)SARS-CoV-2 vaccine (Vero cell), inactivatedInactivated COVID-19 vaccineWhole-virion inactivated SARS-CoV-2 vaccine
02

Targets

SARS-CoV-2 spikeN (Nucleocapsid protein)E (Tick-borne encephalitis virus envelope protein)M protein (SARS-CoV-2 membrane protein)

Beyond the preview

Go deeper on COVID-19 vaccine (Vero cell), inactivated.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVID-19 vaccine (Vero cell), inactivated.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call